Inventor · disambiguated record
Genevieve Mary Weir
Also filed as: WEIR GENEVIEVE · WEIR GENEVIEVE MARY
12 granted patents·11 pending applications·27 citations·filing 2008–2022
88Inventor score
Top patents by PatentIndex Score
23 records- 0184US10232052B2Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivoIMMUNOVACCINE TECHNOLOGIES INC·Filed 2016·Granted Mar 19, 2019·4 cites·27 claims
- 0283US11260116B2Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereofIMMUNOVACCINE TECHNOLOGIES INC·Filed 2017·Granted Mar 1, 2022·2 cites·22 claims
- 0383US11235069B2Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivoIMMUNOVACCINE TECHNOLOGIES INC·Filed 2019·Granted Feb 1, 2022·1 cites·27 claims
- 0483US9498493B2Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivoMANSOUR MARC·Filed 2008·Granted Nov 22, 2016·10 cites·19 claims
- 0582US10729766B2Method for improving the efficacy of a survivin vaccine in the treatment of cancerIMMUNOVACCINE TECHNOLOGIES INC·Filed 2018·Granted Aug 4, 2020·1 cites·28 claims
- 0679US10988500B2Lipid A mimics, methods of preparation, and uses thereofIMMUNOVACCINE TECHNOLOGIES INC·Filed 2019·Granted Apr 27, 2021·1 cites·22 claims
- 0779US10105435B2Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereofIMMUNOVACCINE TECHNOLOGIES INC·Filed 2012·Granted Oct 23, 2018·5 cites·20 claims
- 0870US10022441B2Method for improving the efficacy of a survivin vaccine in the treatment of cancerIMMUNOVACCINE TECHNOLOGIES INC·Filed 2013·Granted Jul 17, 2018·1 cites·29 claims
- 0969US2021322573A1Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivoIMMUNOVACCINE TECHNOLOGIES INC·Filed 2021·Application pending·0 cites
- 1066US11160861B2Adjuvanting systems and water-free vaccine compositions comprising a polyI:C polynucleotide adjuvant and a lipid-based adjuvantIMMUNOVACCINE TECHNOLOGIES INC·Filed 2016·Granted Nov 2, 2021·1 cites·28 claims
- 1166US10533033B2Lipid A mimics, methods of preparation, and uses thereofIMMUNOVACCINE TECHNOLOGIES INC·Filed 2015·Granted Jan 14, 2020·1 cites·35 claims
- 1265US11717563B2Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substanceIMMUNOVACCINE TECHNOLOGIES INC·Filed 2019·Granted Aug 8, 2023·0 cites·26 claims
- 1365US11077184B2Liposome compositions comprising PAM2Cys or PAM3Cys adjuvant and methods for inducing a humoral immune responseIMMUNOVACCINE TECHNOLOGIES INC·Filed 2018·Granted Aug 3, 2021·0 cites·21 claims
- 1465US2011070298A1Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic SubstanceIMMUNOVACCINE TECHNOLOGIES INC·Filed 2009·Application pending·0 cites
- 1564US2021052724A1Method for improving the efficacy of a survivin vaccine in the treatment of cancerIMMUNOVACCINE TECHNOLOGIES INC·Filed 2020·Application pending·0 cites
- 1664US2022143165A1Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereofIMMUNOVACCINE TECHNOLOGIES INC·Filed 2022·Application pending·0 cites
- 1764US2021308252A1Liposome compositions comprising pam2cys or pam3cys adjuvant and methods for inducing a humoral immune responseIMMUNOVACCINE TECHNOLOGIES INC·Filed 2021·Application pending·0 cites
- 1858US2022001010A1Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvantIMMUNOVACCINE TECHNOLOGIES INC·Filed 2021·Application pending·0 cites
- 1951US2022125903A1Methods for improving the efficacy of a survivin therapeutic in the treatment of tumorsIMMUNOVACCINE TECHNOLOGIES INC·Filed 2019·Application pending·0 cites
- 2048US2021147544A1Methods and compositions for targeted delivery of active agents and immunomodulatory agents to lymph nodesIMMUNOVACCINE TECHNOLOGIES INC·Filed 2019·Application pending·0 cites
- 2143US2020230057A1Pharmaceutical Compositions, Methods for Preparation using Lipid Vesicle Particles of Defined Size, and Uses ThereofIMMUNOVACCINE TECHNOLOGIES INC·Filed 2017·Application pending·0 cites
- 2243US2020353062A1Pharmaceutical compositions, methods for preparation comprising sizing of lipid vesicle particles, and uses thereofIMMUNOVACCINE TECHNOLOGIES INC·Filed 2017·Application pending·0 cites
- 2340US2018162913A1Methods for potentiating an immune response using depot-forming and non-depot-forming vaccinesIMMUNOVACCINE TECHNOLOGIES INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Genevieve Mary Weir files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →